Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2010 1
2011 1
2012 1
2013 1
2014 2
2015 2
2016 2
2017 1
2018 4
2019 2
2020 1
2021 6
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy.
Kumagai K, Mariosa D, Tsai JA, Nilsson M, Ye W, Lundell L, Rouvelas I. Kumagai K, et al. Dis Esophagus. 2016 Oct;29(7):734-739. doi: 10.1111/dote.12399. Epub 2015 Aug 28. Dis Esophagus. 2016. PMID: 26316181 Review.
Hazard ratios and risk ratios were calculated to compare the effect of these therapeutic strategies on overall survival and treatment-related mortality, respectively. Four studies containing 219 patients, with persistent or recurrent esophageal squamous ce …
Hazard ratios and risk ratios were calculated to compare the effect of these therapeutic strategies on overall survival and treatment-relate …
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
Ikoma T, Shimokawa M, Matsumoto T, Boku S, Yasuda T, Shibata N, Kurioka Y, Takatani M, Nobuhisa T, Namikawa T, Kitagawa H, Hanazaki K, Doi K, Shimada T, Tsumura T, Marusawa H, Kanaya S, Morita S, Inokuma T, Nagai H, Yasui H, Satake H. Ikoma T, et al. Cancer Immunol Immunother. 2023 Feb;72(2):427-435. doi: 10.1007/s00262-022-03265-7. Epub 2022 Aug 4. Cancer Immunol Immunother. 2023. PMID: 35927359 Free PMC article.
BACKGROUND: In Japan, nivolumab administration is the standard treatment for patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) who are refractory or intolerant to fluoropyrimidines and platinum-based chem …
BACKGROUND: In Japan, nivolumab administration is the standard treatment for patients with unresectable advanced or recurrent esop …
Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy.
Nomura M, Hosokai T, Tamaoki M, Yokoyama A, Matsumoto S, Muto M. Nomura M, et al. Esophagus. 2023 Oct;20(4):722-731. doi: 10.1007/s10388-023-01006-y. Epub 2023 Apr 24. Esophagus. 2023. PMID: 37093536 Free PMC article.
The objective of this study was to clarify whether time-of-day patterns (early or late in the daytime) of the infusion of nivolumab and whether its duration affect treatment efficacy in metastatic or recurrent esophageal squamous cell carcinoma …
The objective of this study was to clarify whether time-of-day patterns (early or late in the daytime) of the infusion of nivolumab and whet …
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Okunaka M, Kotani D, Demachi K, Fujiwara H, Sakashita S, Yoshino T, Fujita T, Kojima T. Okunaka M, et al. Esophagus. 2022 Apr;19(2):240-249. doi: 10.1007/s10388-021-00885-3. Epub 2021 Oct 5. Esophagus. 2022. PMID: 34611830 Free PMC article.
Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study.
Kudou K, Saeki H, Nakashima Y, Kimura Y, Oki E, Mori M, Shimokawa M, Kakeji Y, Toh Y, Doki Y, Matsubara H. Kudou K, et al. Esophagus. 2022 Jan;19(1):57-68. doi: 10.1007/s10388-021-00878-2. Epub 2021 Sep 12. Esophagus. 2022. PMID: 34510325 Free PMC article.
According to multivariate analyses, pN 0-1 (P = 0.0146), lung metastasis (P = 0.0274), recurrence-free interval after curative esophagectomy of 550 days (P = 0.0266), R0 resection (P = 0.0009), and absence of severe complications after resection for recurrent lesions (Clavien-Din …
According to multivariate analyses, pN 0-1 (P = 0.0146), lung metastasis (P = 0.0274), recurrence-free interval after curative esophagectomy …
Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy.
Xu X, Wang Z, Jiang S, Shang Y, Wu Y. Xu X, et al. Radiat Oncol. 2019 Nov 4;14(1):191. doi: 10.1186/s13014-019-1402-1. Radiat Oncol. 2019. PMID: 31684983 Free PMC article.
BACKGROUND: Re-irradiation (re-RT) has the active effect of relieving clinical symptoms and prolonging the survival of patients with recurrent esophageal squamous cell carcinoma (ESCC). However, the optimal re-RT dose is still uncertain. ...
BACKGROUND: Re-irradiation (re-RT) has the active effect of relieving clinical symptoms and prolonging the survival of patients with recu …
A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.
Wu X, Hu X, Chen J, He L. Wu X, et al. Radiat Oncol. 2021 Jun 8;16(1):100. doi: 10.1186/s13014-021-01828-z. Radiat Oncol. 2021. PMID: 34103059 Free PMC article.
The current study aimed to determine the optimal re-irradiation dose for local recurrent esophageal squamous cell carcinoma (LRESCC) following radical (chemo) radiotherapy. ...
The current study aimed to determine the optimal re-irradiation dose for local recurrent esophageal squamous cell …
26 results